$234.79
0.39% today
Nasdaq, Sep 16, 08:15 pm CET
ISIN
US45784P1012
Symbol
PODD

Insulet Corporation Stock price

$233.87
+39.28 20.19% 1M
+58.33 33.23% 6M
+16.89 7.78% YTD
+56.89 32.14% 1Y
-61.23 20.75% 3Y
+90.63 63.27% 5Y
+200.93 609.99% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+3.42 1.48%
ISIN
US45784P1012
Symbol
PODD
Sector

Key metrics

Market capitalization $16.40b
Enterprise Value $16.97b
P/E (TTM) P/E ratio 42.47
EV/FCF (TTM) EV/FCF 88.87
EV/Sales (TTM) EV/Sales 9.06
P/S ratio (TTM) P/S ratio 8.76
P/B ratio (TTM) P/B ratio 16.42
Revenue growth (TTM) Revenue growth 27.82%
Revenue (TTM) Revenue $1.87b
EBIT (operating result TTM) EBIT $272.70m
Free Cash Flow (TTM) Free Cash Flow $191.00m
Cash position $821.00m
EPS (TTM) EPS $5.51
P/E forward 77.81
P/S forward 8.13
EV/Sales forward 8.42
Short interest 5.56%
Show more

Is Insulet Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Insulet Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Insulet Corporation forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Insulet Corporation forecast:

Buy
88%
Hold
13%

Financial data from Insulet Corporation

Jun '24
+/-
%
Net Profit 395 395
528% 528%
21%
Depreciation and Amortization 76 76
18% 18%
4%
Stock Compensation 54 54
20% 20%
3%
Operating Cash Flow 285 285
88% 88%
15%
Investments 103 103
42% 42%
5%
Dividend Paid - -
-
-
Free Cash Flow 191 191
532% 532%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Insulet Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insulet Corporation Stock News

Positive
Forbes
17 days ago
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over this period.
Positive
The Motley Fool
17 days ago
The highly specialized medical device maker earns an important nod from a top regulator. A label expansion could potentially reach a market of 6 million people.
Positive
Investopedia
20 days ago
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later in the week.
More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office United States
CEO James Hollingshead
Employees 3,000
Founded 2000
Website www.insulet.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today